BioMérieux: Invest Securities confirms rating

(CercleFinance.com) - Invest Securities confirms its sell rating on the BioMérieux share, although has upped its corresponding target price to 57 euros (vs.
51 euros).

The broker considers that the share's current valuation remains excessive, leaving little leeway for disappointment.

Analysts say the group released 2018 results at the end of February which exceeded expectations, thanks to a robust fourth quarter (+10.2% l-f-l), while the guidance for 2019 is in line with expectations.

Targets for 2019 highlight (i) a slowdown in l-f-l growth to +7%/+8.5% (vs. +9.9% in 2018), mainly due to the limited influenza epidemic in 2019, and (ii) a stabilisation in the group's EBITA margin at 14.9%, the broker says.



Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.